ReviewCardiovascular diabetology2025
Ferroptosis in the pathogenesis of diabetic cardiomyopathy: mechanisms and therapeutic potential.
Review in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Baicalein Attenuates High Glucose and Sodium Palmitate-Induced Ferroptosis in Cardiomyocytes via the Nrf2/SLC7A11/GPX4 Signaling Pathway.International journal of molecular sciences · 2026Article
- Article
- Transcriptional Heterogeneity of Cardiac Remodeling Between Type 1 and Type 2 Diabetes.Biomedicines · 2026Article
- Ion channels and GPCRs as pharmacological regulators of ferroptosis and pyroptosis in metabolic diseases.Diabetology & metabolic syndrome · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus, often leading to heart failure and increased mortality. While its pathogenesis remains incompletely understood, key contributors include chronic hyperglycemia, hyperlipidemia, insulin resistance, myocardial fibrosis, oxidative stress, mitochondrial dysfunction, and aberrant cell death pathways. Emerging evidence highlights ferroptosis, an iron-dependent form of regulated cell death, as a critical player in DCM progression. This review synthesizes current knowledge on the mechanistic links between ferroptosis and DCM, focusing on endothelial dysfunction, myocardial fibrosis, oxidative stress, and mitochondrial damage. We also discuss promising therapeutic strategies targeting ferroptosis to alleviate DCM, including pharmacological inhibitors, natural compounds, and non-coding RNAs, while identifying gaps for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.